DOH warns the public against overprice Remdesivir

Share on facebook
Share on twitter
Share on email

The Department of Health warns the public on overpricing of Remdesivir, an investigational drug for COVID-19 that requires compassionate use permit from the Food and Drug Administration.

DOH said per Rule XII, Section 1 of DTI, DA, DOH, DENR Joint Administrative Order No. 1 S. 1993,
“Any person found to have committed any illegal act of price manipulation as defined and prohibited under Section 5 of RA 7581, as amended, shall be penalized administratively and criminally.”

In an advisory, the health department said the lowest suggested retail price for a 100mg vial of Remdesivir is at P1,500 with the highest retail price cap at P8,200.

A COVID patient admitted in a medical facility is normally prescribed to complete at least 6 vials of Remdesivir as part of compassionate medical care.

DOH said those who may have been a victim of overpricing may file their complaints by emailing